# A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

> **NCT02531373** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 338 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** V114 Medium Dose
- **BIOLOGICAL:** V114 High Dose
- **BIOLOGICAL:** V114 Medium Dose with Alternative Carrier Protein
- **BIOLOGICAL:** V114 High Dose with Alternative Carrier Protein
- **BIOLOGICAL:** Prevnar 13™

## Key facts

- **NCT ID:** NCT02531373
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-15
- **Primary completion:** 2017-04-14
- **Final completion:** 2017-04-14
- **Target enrollment:** 338 (ACTUAL)
- **Last updated:** 2019-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02531373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02531373, "A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02531373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*